Several participants who began the intervention from a chair were completing the exercise standing up by the end.
Notably, results were achieved without maintenance therapy.
There was a significant association between the average GCIP thickness and MSFC scores.
The new drug shows promise in the treatment of PPMS, for which there are currently no approved treatments.
The material of the device may play a significant role in the relationship.
Patients taking oral DMDs were more likely to experience relapse in the first year.
A comprehensive approach to managing depression may have far-reaching effects.
At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.
Early screening is paramount to identifying patients at risk for suicide.
Neurology Advisor reviews the upcoming agenda for the CMSC annual meeting.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies